Deferred Tax Assets, Valuation Allowance of Estrella Immunopharma, Inc. from 30 Sep 2021 to 31 Dec 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary: Estrella Immunopharma, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 30 Sep 2021 to 31 Dec 2024.
Estrella Immunopharma, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $5,403,415.
Source SEC data: View on sec.gov

Deferred Tax Assets, Valuation Allowance, Quarterly (USD)

Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Estrella Immunopharma, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q4 2024	$5,403,415			31 Dec 2024	10-KT	25 Mar 2025	2024	FY
Q2 2024	$4,479,150	+$1,919,554	+75%	30 Jun 2024	10-KT	25 Mar 2025	2024	FY
Q2 2023	$2,559,596	+$2,402,399	+1528%	30 Jun 2023	10-K	27 Sep 2024	2024	FY
Q1 2023	$318,310	+$233,626	+276%	31 Mar 2023	10-Q	18 May 2023
Q4 2022	$292,154	+$240,133	+462%	31 Dec 2022	10-Q	01 Aug 2023	2023	Q2
Q3 2022	$229,618	+$206,115	+877%	30 Sep 2022	10-Q	14 Nov 2022	2022	Q3
Q2 2022	$157,197			30 Jun 2022	10-Q	08 Aug 2022	2022	Q2
Q1 2022	$84,684			31 Mar 2022	10-Q	16 May 2022	2022	Q1
Q4 2021	$52,021			31 Dec 2021	10-K	14 Mar 2023	2022	FY
Q3 2021	$23,503			30 Sep 2021	10-Q	10 Nov 2021	2021	Q3

* An asterisk sign (*) next to the value indicates that the value is likely invalid.